Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease

Respiratory Medicine

Volumn 106, Issue 12, 2012, Pages 1810-1813

  Maier, Lisa A ^a,b   Barkes, Briana Q ^a   Mroz, Margaret ^a   Rossman, Milton D ^c   Barnard, Juliana ^a   Gillespie, May ^a   Martin, Allison ^a   MacK, Douglas G ^a   Silveira, Lori ^d   Sawyer, Richard T ^a   Newman, Lee S ^a,b   Fontenot, Andrew P ^a,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Food Science and Human Nutrition   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; PLACEBO;

ADULT; AGED; BERYLLIOSIS; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; EXERCISE; FEMALE; HUMAN; IMMUNOMODULATION; LETTER; LUNG ALVEOLUS OXYGEN TENSION; LUNG FUNCTION; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BERYLLIOSIS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 84867748077     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.08.014     Document Type: Letter

References (30)

1. P.K.G. Henneberger, K. Sandra, William E. Miller, Brent Doney, and Dennis W. Groce Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed J Occup Environ Hyg 1 2004 648 659
2. G.M. Samuel, and A. Lisa Immunology of chronic beryllium disease Curr Opin Allergy Clin Immunol 8 2008 126 134
3. C.R.K. Schuler, S. Michael, David C. Deubner, Michael T. Berakis, Michael McCawley, Paul K. Henneberger, Milton D. Rossman, and Kathleen Kreiss Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility Am J Ind Med 47 2005 195 205
4. P.K.C. Henneberger, Debra, David D. Deubner, Michael S. Kent, Michael McCawley, and Kathleen Kreiss Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant Int Arch Occup Environ Health 74 2001 167 176
5. E.M.B. Daniloff, Becki Bucher, John D. Newell Jr., Steven M. Bernstein, and Lee S. Newman Observer variation and relationship of computed tomography to severity of beryllium disease Am J Respir Crit Care Med 155 1997 2047 2056
6. M.D. Duggal, C. David, Anne M. Curtis, and Mark R. Cullen Long-term follow-up of beryllium sensitized workers from a single employer BMC Public Health 10 5 2010 1 10
7. M.M.M. Mroz, A. Lisa, Matthew Strand, Lori Silviera, and Lee S. Newman Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease Am J Ind Med 52 10 2009 762 773
8. L.S.M. Newman, M. Margaret, Ronald Balkissoon, and Lisa A. Maier Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study Am J Respir Crit Care Med 171 2005 54 60
9. G.P.N. Pappas, and S. Lee Early pulmonary physiologic abnormalities in beryllium disease Am Rev Respir Dis 148 1993 661 666
10. S. Marchand-Adam, A. El Khatib, and F. Guillon Short- and long-term response to corticosteroid therapy in chronic beryllium disease Eur Respir J 32 3 2008 687 693
11. A.B. Sood, S. William, and Mark R. Cullen Variable response to long-term corticosteroid therapy in chronic beryllium disease Chest 126 6 2004 2000 2007
12. S. Paramothayan, and P.W. Jones Corticosteroid therapy in pulmonary sarcoidosis: a systematic review J Am Med Assoc 287 10 2002 1301 1307
13. G.J. Gibson, R.J. Prescott, and M.F. Muers British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment Thorax 51 3 1996 238 247
14. R.P.L. Baughman, and E. Elyse A clinical approach to the use of methotrexate for sarcoidosis Thorax 54 1999 742 746
15. R.P. Baughman, and E.E. Lower Steroid-sparing alternative treatments for sarcoidosis Clin Chest Med 18 4 1997 853 864
16. E. Daniloff Methotrexate treatment in chronic beryllium disease Am J Respir Crit Care Med 157 1998 A146
17. R.P.D. Baughman, Marjolein, Mani Kavuru, Marc Judson, Ulrich Costablel, Roland du Bois, Carlo Albera, Martin Brutsche, Gerald Davis, James F. Donohue, Joachim Muller-Quernheim, Rozsa Schlenker-Herceg, Susan Flavin, Kim Hung Lo, Barry Oemar, Elliot S. Barnatha on behalf of the Sarcoidosis Investigators Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement Am J Respir Crit Care Med 174 2006 795 802
18. L.A.S. Maier, T. Richard, Roslyn A. Bauer, Lori A. Kittle, Penny Lympany, Deirdre McGrath, Roland Dubois, Elaine Daniloff, Cecile S. Rose, and Lee S. Newman High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease Am J Respir Crit Care Med 164 2001 1192 1199
19. E.D. Crouser, M.W. Julian, G. Shao, C. Fox, D. Hauswirth, J. Jehn, G. Lozanski, S. Erdal, and M.D. Wewers Infliximab reverses Peripheral CD4+ T cell depletion in lymphopenic sarcoidosis patients Am J Respir Crit Care Med 179 2009 A2255
20. M.R.E. Ehrenstein, G. Jamie, Animesh Singh, Samantha Moore, Gary Warnes, David A. Isenberg, and Claudia Mauri Compromised function of regulatory T cells n rheumatoid arthritis and reversal by ANti-TNF alpha therapy J Exp Med 200 3 2004 277 285
21. S.M. Nadkarni, Claudia, and Michael R. Ehrenstein Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β J Exp Med 204 1 2007 33 39
22. D.G.L. Mack, M. Allison, Michael T. Falta, Brent E. Palmer, Lisa A. Maier, and Andrew P. Fontenot Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects Am J Respir Crit Care Med 181 2010 1241 1249
23. S.B.L. Hanauer, R. Gary, Lloyd F. Mayer, S. Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C. Wolf, Allan Olson, Welhang Bao, Paul Rutgeerts the ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT I randomised trail Lancet 359 2002 1541 1549
24. B.E.A. Sands, H. Frank, Charles N. Bernstein, William Y. Chey, Brian G. Feagan, Richard N. Fedorak, Michael A. Kamm, Joshua R. Korzenik, Bret A. Lashner, Jane E. Onken, Daniel Rachmilewitz, Paul Rutgeerts, Gary Wild, Douglas C. Wolf, Paul A. Marsters, Suzanne B. Travers, MArion A. Blank, and Sander J. van Deventer Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 9 2004 876 885
25. G.R. Lichtenstein, S. Yan, M. Bala, and S. Hanauer Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries Am J Gastroenterol 99 1 2004 91 96
26. P.E.V.D.H. Lipsky, Desiree, E. William St. Clair, Daniel E. Furst, Ferdinand C. Breedveld, Joachim Kalden, Josef S. Smolen, Michael Weisman, Paul Emery, Marc Feldmann, Gregory R. Harriman, Ravinder Maini for the Anti-Tumor Necrosis Factor Trial in Rheumatoid ARthritis with Concomitant Therapy Study Group INfliximab and MEthotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 22 2000 1594 1602
27. C.S. Han, S. Josef, Arthur Kavanaugh, Desiree van der Heijde, Jurgen Braun, Rene Westhovens, Ning Zhao, Mahboob U. Rahman, Daniel Baker, and Mohan Bala The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases Arthritis Res Ther 9 R103 2007 1 6
28. A. Kavanaugh Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis Ann Rheum Dis 65 4 2005 471 477
29. D.G. Contopoulos-Ioannidis, A. Karvouni, I. Kouri, and J.P. Ioannidis Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review BMJ 338 2009 a3006
30. F. Wolfe, K. Michaud, O. Gefeller, and H.K. Choi Predicting mortality in patients with rheumatoid arthritis Arthritis Rheum 48 6 2003 1530 1542